Pharmacovigilance in Covid-19 vaccines

The ongoing pandemic coronavirus disease of 2019 (COVID-19), originated from Wuhan, China, has caused universal challenging and threatening with considerable health impact and economic losses. Therefore, vaccination, as preventive and protective medical countermeasure, remains an excellent issue for...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bahouq Hanane, Bahouq Madiha, Soulaymani Abdelmajid, Soulaymani-Bencheikh Rachida
Formato:	article
Lenguaje:	EN FR
Publicado:	EDP Sciences 2021
Materias:	Environmental sciences GE1-350
Acceso en línea:	https://doaj.org/article/fef1dbd540c04a9e93d87fd43239243a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fef1dbd540c04a9e93d87fd43239243a
record_format	dspace
spelling	oai:doaj.org-article:fef1dbd540c04a9e93d87fd43239243a2021-11-12T11:44:08ZPharmacovigilance in Covid-19 vaccines2267-124210.1051/e3sconf/202131901012https://doaj.org/article/fef1dbd540c04a9e93d87fd43239243a2021-01-01T00:00:00Zhttps://www.e3s-conferences.org/articles/e3sconf/pdf/2021/95/e3sconf_vigisan_01012.pdfhttps://doaj.org/toc/2267-1242The ongoing pandemic coronavirus disease of 2019 (COVID-19), originated from Wuhan, China, has caused universal challenging and threatening with considerable health impact and economic losses. Therefore, vaccination, as preventive and protective medical countermeasure, remains an excellent issue for reducing morbidity and mortality of this emerging infectious disease. As of April 2021 and by Emergency Use Authorization (EUA) process, 16 vaccines were authorized by at least one national regulatory authority for public use: two Ribonucleic Acid (RNA) vaccines (Pfizer–BioNTech and Moderna), seven conventional inactivated vaccines (BBIBP-CorV manufactured by Siinopharm, CoronaVac, Covaxin, WIBP-CorV, CoviVac, Minhai-Kangtai and QazVac), five viral vector vaccines (Sputnik Light, Sputnik V, Oxford–AstraZeneca, Convidecia, and Johnson & Johnson) and two protein subunit vaccines (EpiVacCorona and RBD-Dimer). As other countries, Morocco has established an anti-COVID-19 vaccine strategy in order to effectively contribute to the monitoring of vaccine safety supported by the national platform health vigilance and regulated by the National Anti-Poison and Pharmacovigilance Center (CAPM). In this review, we recorded the main current developed COVID-19 vaccines and discussed pharmacovigilance strategies and tools related safety and tolerability of those therapies. In parallel, a review of the Moroccan experience in this field is also conducted.Bahouq HananeBahouq MadihaSoulaymani AbdelmajidSoulaymani-Bencheikh RachidaEDP SciencesarticleEnvironmental sciencesGE1-350ENFRE3S Web of Conferences, Vol 319, p 01012 (2021)
institution	DOAJ
collection	DOAJ
language	EN FR
topic	Environmental sciences GE1-350
spellingShingle	Environmental sciences GE1-350 Bahouq Hanane Bahouq Madiha Soulaymani Abdelmajid Soulaymani-Bencheikh Rachida Pharmacovigilance in Covid-19 vaccines
description	The ongoing pandemic coronavirus disease of 2019 (COVID-19), originated from Wuhan, China, has caused universal challenging and threatening with considerable health impact and economic losses. Therefore, vaccination, as preventive and protective medical countermeasure, remains an excellent issue for reducing morbidity and mortality of this emerging infectious disease. As of April 2021 and by Emergency Use Authorization (EUA) process, 16 vaccines were authorized by at least one national regulatory authority for public use: two Ribonucleic Acid (RNA) vaccines (Pfizer–BioNTech and Moderna), seven conventional inactivated vaccines (BBIBP-CorV manufactured by Siinopharm, CoronaVac, Covaxin, WIBP-CorV, CoviVac, Minhai-Kangtai and QazVac), five viral vector vaccines (Sputnik Light, Sputnik V, Oxford–AstraZeneca, Convidecia, and Johnson & Johnson) and two protein subunit vaccines (EpiVacCorona and RBD-Dimer). As other countries, Morocco has established an anti-COVID-19 vaccine strategy in order to effectively contribute to the monitoring of vaccine safety supported by the national platform health vigilance and regulated by the National Anti-Poison and Pharmacovigilance Center (CAPM). In this review, we recorded the main current developed COVID-19 vaccines and discussed pharmacovigilance strategies and tools related safety and tolerability of those therapies. In parallel, a review of the Moroccan experience in this field is also conducted.
format	article
author	Bahouq Hanane Bahouq Madiha Soulaymani Abdelmajid Soulaymani-Bencheikh Rachida
author_facet	Bahouq Hanane Bahouq Madiha Soulaymani Abdelmajid Soulaymani-Bencheikh Rachida
author_sort	Bahouq Hanane
title	Pharmacovigilance in Covid-19 vaccines
title_short	Pharmacovigilance in Covid-19 vaccines
title_full	Pharmacovigilance in Covid-19 vaccines
title_fullStr	Pharmacovigilance in Covid-19 vaccines
title_full_unstemmed	Pharmacovigilance in Covid-19 vaccines
title_sort	pharmacovigilance in covid-19 vaccines
publisher	EDP Sciences
publishDate	2021
url	https://doaj.org/article/fef1dbd540c04a9e93d87fd43239243a
work_keys_str_mv	AT bahouqhanane pharmacovigilanceincovid19vaccines AT bahouqmadiha pharmacovigilanceincovid19vaccines AT soulaymaniabdelmajid pharmacovigilanceincovid19vaccines AT soulaymanibencheikhrachida pharmacovigilanceincovid19vaccines
_version_	1718430655845498880

Pharmacovigilance in Covid-19 vaccines

Ejemplares similares